Nanobiotix Closes Global Offering, Raises Approximately $100 Million
Biotechnology firm Nanobiotix announced the completion of its global offering of shares and pre-funded warrants, raising approximately $100 million in gross proceeds.
Biotechnology company Nanobiotix announced on May 26, 2026, the closing of its global offering, which raised approximately $100 million in gross proceeds. The offering included ordinary shares and pre-funded warrants, with underwriters fully exercising their option to purchase additional American Depositary Shares (ADSs).
The company intends to use the net proceeds to advance its JNJ-1900 (NBTXR3) program, support the development of its Nanoprimer and other platforms, and for general corporate purposes. Nanobiotix stated that the funds, combined with existing cash, are expected to cover working capital requirements into 2029.
The offering's subscription price per ordinary share was set at €33.60, equivalent to $38.98 per ADS, based on a specific exchange rate used during the pricing. This price was determined based on the volume-weighted average price of ordinary shares on Euronext Paris over the three preceding trading sessions, minus a discount.
Nanobiotix, which is developing physics-based approaches for cancer treatment, has its ADSs listed on the Nasdaq Global Select Market under the symbol NBTX and its ordinary shares on Euronext Paris under the symbol NANO. Jefferies, TD Cowen, and Stifel acted as the global coordinators and joint bookrunners for the offering.